BackPhoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) Overview
Phoenix Biotech Acquisition Corp - Units (1 Ord Class A & 1/2 War)

Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) P/E Ratio

Valuation check: PBAXU's P/E ratio is -0.27, below the sector sector average of 34.88.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-0.27

P/E Ratio

-0.27

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) (PBAXU) FAQ

The latest P/E ratio for PBAXU is -0.27. That is below the sector sector average of 34.88. Investors often review this figure alongside Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, PBAXU currently prints -0.27 for P/E ratio, while the sector average sits near 34.88. That is roughly 100.8% below the sector mean. Large gaps often invite a closer look at Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War)'s growth, margins, and balance sheet.

A P/E ratio of -0.27 for Phoenix Biotech Acquisition - Units (1 Ord Class A & 1/2 War) is not 'good' or 'bad' on its own. Compare it with the peer average (34.88) and with PBAXU's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting PBAXU's P/E ratio (-0.27), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.